Jade Biosciences, Inc.
Jade Biosciences, Inc. (JBIO): 4 pipeline candidates · ~38 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
37.5 months
D/E 0.08 · 17% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Jade Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$989.0M
Cash
$55.1M
Quarterly Burn
$24.1M
Runway
37.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
118
Total value held
$625.0M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,085,423 | $99.6M |
| janus henderson group plc | 6,211,338 | $87.1M |
| avidity partners management lp | 2,801,416 | $53.9M |
| ra capital management, l.p. | 3,671,083 | $51.6M |
| vanguard capital management llc | 3,593,304 | $50.5M |
| blackrock, inc. | 2,313,949 | $32.5M |
| baker bros. advisors lp | 1,641,137 | $23.1M |
| versant venture management, llc | 1,525,820 | $21.4M |
| samsara biocapital, llc | 968,798 | $13.6M |
| great point partners llc | 964,462 | $13.6M |
Showing top 10 of 118 institutional holders of Jade Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Jade Biosciences, Inc.'s pipeline?
Jade Biosciences, Inc. (JBIO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Jade Biosciences, Inc.'s lead drug candidate?
Jade Biosciences, Inc.'s most advanced tracked candidate is av-101 (Preclinical) for pulmonary arterial hypertension.
What is Jade Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Jade Biosciences, Inc. has approximately 37.5 months of cash runway.
What is Jade Biosciences, Inc.'s market capitalization?
Jade Biosciences, Inc.'s market capitalization is approximately $989.0M.
Who is the CEO of Jade Biosciences, Inc.?
Mr. Tom Frohlich is the chief executive officer of Jade Biosciences, Inc. (JBIO).
Get the full picture on Jade Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.